LONA LeonaBio Inc.

Price (delayed)

$8.61

Market cap

$80.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$24.11

Enterprise value

$48.11M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain ...

Highlights
LONA's equity has soared by 77% from the previous quarter and by 32% YoY
LONA's quick ratio has soared by 51% YoY
The EPS is down by 17% YoY but it is up by 2.4% QoQ
LONA's net income has dropped by 62% year-on-year and by 23% since the previous quarter

Key stats

What are the main financial stats of LONA

LONA stock price

How has the LeonaBio stock price performed over time
Intraday
-0.23%
1 week
-10.68%
1 month
-9.84%
1 year
160.91%
YTD
13.74%
QTD
-16.25%

Financial performance

How have LeonaBio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$109.94M
Net income
-$129.41M
Gross margin
N/A
Net margin
N/A
LONA's net income has dropped by 62% year-on-year and by 23% since the previous quarter
LONA's operating income is down by 33% YoY and by 8% from the previous quarter

Price vs fundamentals

How does LONA's price correlate with its fundamentals

Growth

What is LeonaBio's growth rate over time

Valuation

What is LeonaBio stock price valuation
P/E
N/A
P/B
1.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 17% YoY but it is up by 2.4% QoQ
LONA's P/B is 105% above its 5-year quarterly average of 0.8 and 64% above its last 4 quarters average of 1.0
LONA's equity has soared by 77% from the previous quarter and by 32% YoY

Efficiency

How efficient is LeonaBio business performance
LONA's return on equity has dropped by 166% year-on-year and by 12% since the previous quarter
LeonaBio's ROA has plunged by 112% YoY and by 8% from the previous quarter
The ROIC has soared by 67% from the previous quarter

Dividends

What is LONA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LONA.

Financial health

How did LeonaBio financials performed over time
The total assets has soared by 65% year-on-year but it has declined by 22% since the previous quarter
LONA's total liabilities has dropped by 65% since the previous quarter
The company's debt is 99% lower than its equity
LONA's equity has soared by 77% from the previous quarter and by 32% YoY
The company's debt to equity has shrunk by 67% QoQ and by 67% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.